Date published: 2026-3-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

IRF-4 Inhibitors

Interferon Regulatory Factor 4 (IRF-4) is a member of the interferon regulatory factor (IRF) family of transcription factors. IRFs play critical roles in the regulation of genes involved in immune responses, cell growth, and hematopoietic development. IRF-4, in particular, is essential for the differentiation and function of various immune cells, especially B cells, T cells, and dendritic cells. The protein is induced by signals that lead to lymphocyte activation, and it subsequently regulates the expression of genes that are vital for immune cell function. Moreover, IRF-4 is involved in the regulation of cytokine gene expression and has been implicated in controlling the balance between Th1 and Th2 cell responses. Given its central role in immune system regulation, the precise modulation of IRF-4 activity is of paramount importance for maintaining immune homeostasis and ensuring appropriate responses to pathogens.

IRF-4 inhibitors are a class of chemical compounds designed to target and modulate the activity or expression of IRF-4. These inhibitors can function through diverse mechanisms. Some might bind directly to IRF-4, blocking its DNA-binding domain and thereby preventing it from modulating the transcription of its target genes. Others might interfere with the interaction between IRF-4 and its co-factors or partner proteins, disrupting the formation of functional transcriptional complexes. Additionally, some inhibitors might target the signaling pathways that regulate the expression or post-translational modifications of IRF-4, leading to altered levels or activity of the transcription factor.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lenalidomide

191732-72-6sc-218656
sc-218656A
sc-218656B
10 mg
100 mg
1 g
$50.00
$374.00
$2071.00
18
(1)

Lenalidomide has been shown to degrade IRF-4 via the cereblon pathway, leading to reduced protein expression in multiple myeloma cells.

Pomalidomide

19171-19-8sc-364593
sc-364593A
sc-364593B
sc-364593C
sc-364593D
sc-364593E
5 mg
10 mg
50 mg
100 mg
500 mg
1 g
$100.00
$143.00
$312.00
$468.00
$1248.00
$1997.00
1
(1)

Similar to lenalidomide, pomalidomide induces the degradation of IRF-4 in multiple myeloma cells through the cereblon pathway.

I-BET 151 Hydrochloride

1300031-49-5 (non HCl Salt)sc-391115
10 mg
$450.00
2
(0)

I-BET151, a BET bromodomain inhibitor, suppresses IRF-4 transcription, leading to reduced expression in multiple myeloma cells.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$231.00
$863.00
1
(0)

JQ1, a BET bromodomain inhibitor, down-regulates IRF-4 transcription and reduces its expression in hematologic malignancies.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$66.00
$325.00
$587.00
$1018.00
28
(1)

All-trans retinoic acid (ATRA) can modulate the differentiation of immune cells, potentially suppressing IRF-4 expression in certain contexts.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

Ruxolitinib, a JAK1/2 inhibitor, can suppress IRF-4 expression in JAK-STAT signaling-associated conditions.

AZD1480

935666-88-9sc-364735
sc-364735A
5 mg
50 mg
$124.00
$1072.00
11
(2)

AZD1480, a JAK1/2 inhibitor, can down-regulate IRF-4 in conditions with aberrant JAK-STAT signaling.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Ibrutinib targets BTK and could indirectly reduce IRF-4 expression in B-cell malignancies.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib, a tyrosine kinase inhibitor, can impact various signaling pathways and may reduce IRF-4 expression in certain contexts.